



**THERMOGENESIS CORP. COMPLETES ENROLLMENT OF
150-PATIENT HUMAN CLINICAL TRIAL OF
CRYOSEAL® FIBRIN SEALANT SYSTEM**

RANCHO CORDOVA, California (June 22, 2005) – ThermoGenesis Corp. (NASDAQ: KOOL) announced today that enrollment is now complete for its pivotal U.S. 150-patient blinded, randomized, multi-center clinical trial for the CryoSeal Fibrin Sealant (FS) System. This pivotal trial evaluated the safety and efficacy of the Fibrin Sealant prepared by the CryoSeal FS System as an adjunct to hemostasis for patients undergoing liver resection surgery. The data will be compiled and included in a PMA submission expected to be filed in calendar 2005. The review process after a PMA submission typically takes six months.

FDA clearance will allow the company to address the \$125 million U.S. fibrin sealant market as well as that of other countries that require FDA clearance of U.S. products before allowing them to be marketed within their borders. The worldwide market for fibrin sealant is in excess of \$450 million per year.

This clinical trial was managed by Quintiles Inc., the North American clinical development subsidiary of Quintiles Transnational Corp., who engaged ten (10) prominent cancer centers including; Cedars-Sinai Medical Center, Johns Hopkins Cancer Center, Lahey Clinic, Memorial Sloan-Kettering Cancer Center, New York University Medical Center, University of California Los Angeles Dumont Liver Cancer Center, University of Louisville School of Medicine, University of Miami Sylvester Cancer Center, University of Southern California Medical Center and Vanderbilt University Medical Center.

Kevin Simpson, President and COO of ThermoGenesis Corp. noted that “We are extremely pleased and satisfied to complete the Company’s long awaited PMA clinical trial enrollment utilizing the CryoSeal autologous fibrin sealant system for liver resection surgeries. There are ten (10) prominent liver cancer centers that were uniquely qualified to perform these extensive surgeries. I want to especially acknowledge the hard work and diligence of the Principal Investigators and Coordinators from all the sites in recruiting patients and adhering so well to the detailed clinical protocol throughout the trial period. We look forward to receiving their assessment of the clinical performance of our technology.”

The CryoSeal FS System prepares both components (cryoprecipitate and thrombin) of CryoSeal Fibrin Sealant from a single unit of autologous human plasma in about an hour. Once prepared, the CryoSeal Fibrin Sealant may be frozen or used immediately as a hemostatic agent for patients undergoing liver resection surgery.

In contrast, conventional fibrin sealants are sourced from large pools of 10,000 or more units of purchased plasma, and thus remain vulnerable to contamination by infectious pathogens residing in any of these 10,000 units of blood plasma. There have been several recent peer review Journal reports of the transmission of Parvo virus B-19 to surgical patients receiving conventional fibrin sealant. In addition, conventional fibrin sealants often contain animal proteins such as bovine aprotinin. Animal proteins are a potential source of agents of transmissible bovine spongiform encephalopathy (BSE) which are resistant to any methods of pathogen inactivation available to fractionators at this time.

Regulatory Status

ThermoGenesis Corp. has been granted the right to affix the CE Mark to the CryoSeal FS System by our European Notified Body. The product is being tested in European clinical trials. Additional field trials are underway in Canada and Brazil. In Japan, the pivotal clinical trial was completed in late 2004 and the PMA filed in March 2005. Sales in the U.S. must follow FDA approval. The submission of a PMA is expected in 2005 and FDA approval to market is anticipated in 2006.

About ThermoGenesis Corp.

ThermoGenesis Corp. is a leader in enabling technologies for cell therapeutics. The Company's technology platforms lead the world in their ability to produce biological products from single units of blood. Umbilical cord blood banks are utilizing the Company's BioArchive® System as a critical enabling technology for cryogenic archiving of stem cells for transplant, while its CryoSeal FS System is used to prepare hemostatic and adhesive surgical sealants from the patient's blood in about an hour.

ThermoGenesis Corp. has been a leading supplier of state-of-the-art Ultra-Rapid Blood Plasma Freezers and Thawers to hospitals and blood banks since 1992.

The statements contained in this release which are not historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond the company's control with respect to market acceptance of new technologies and products, delays in testing and evaluation of products, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission.

More Information, Contact:

ThermoGenesis Corp.
Kevin Simpson: (916) 858-5100